FENC

Fennec Pharmaceuticals

Fundamental data last updated:March 2, 2026

We may earn a commission from partner links. This content is for informational purposes only and is not financial advice. Information may be delayed or inaccurate.

company profile

SECTOR

Healthcare

industry

Biotechnology

Exchange

Nasdaq

County of HQ

United States

Next Earnings Date

8

Business Summary

Fennec Pharmaceuticals is a biopharmaceutical company focused on the development and commercialization of drug candidates for pediatric cancer. Its lead product is designed to prevent hearing loss associated with cisplatin chemotherapy in children with localized, non-metastatic solid tumors.

 


Analyze FENC on TradingView

VALUATION

P/E

-

Market Cap ($M USD)

$285

Forward P/E

13.6

PEG

1.2

PRICE TO SALES

6

PRICE TO BOOK

-

EV / EBITDA

5-Year Average P/E

Free Cash Flow Yield

DCF Value

Graham Number

Price to FCF

EV to FCF

Earnings Yield

FCF Yield

DIVIDEND

Yield

-

Annual Payout

-

Payout Ratio

-

Consecutive Years of Dividend Growth

0

5-Year Dividend Growth Rate

-

Financial Health & Profitability

Earnings Per Share

-$0.26

Next Year EPS Growth Estimate

$0.63

Next Year Revenue Growth Estimate

68.90%

Return on Equity (ROE)

154.50%

FREE CASH FLOW

Operating Margin

-12.20%

Debt-to-Equity

-

Piotroski F-Score

Altman Z-Score

Return on Invested Capital (ROIC)

Current Ratio

Quick Ratio

Net Debt to EBITDA

Interest Coverage

Gross Profit margin

FCF PER SHARE

REVENUE PER SHARE

Analyze FENC on TradingView

Gainseekers Quantitative Analysis

Summary

Fennec Pharmaceuticals is a $285 million market cap biotechnology company that is currently unprofitable, with an EPS of -$0.26 and a negative operating margin of -12.20%. The company is expected to become profitable next year, with analysts forecasting sales growth of 68.90% and an EPS of $0.63.

AI Exposure / Tech Reliance

The provided financial data does not contain specific metrics regarding AI exposure or technology reliance.

The Bull Case

The bull case is supported by a strong sales growth forecast of 68.90% and an estimated EPS of $0.63 for next year. Analyst sentiment is also very strong, with a consensus rating of 1.25 and a mean consensus target price of $15.29.

The Bear Case

The company is currently unprofitable, evidenced by an EPS of -$0.26, a negative operating margin of -12.20%, and no available Price / Earnings or Price / Book ratios. The Price / Sales ratio of 6 is notable for a company that is not yet generating positive earnings.

Market Sentiment & Smart Money

Short Interest %

3.00%

Analyst Consensus

1.25

Average Analyst Price Target

$15.29

Institutional Ownership %

53.30%

1-Year Beta

Insider Buying % (6 Mo)

Distance to 52-Week High

Distance to 52-Week Low

EARNINGS SURPRISE %

50-DAY SMA

200-DAY SMA

⚠️ Financial Disclaimer:
This content is for informational purposes only and is not financial advice. Information may be delayed or inaccurate. We may earn a commission from partner links.